
<html>

<head>





</head>

<body lang="EN-US" link="blue" vlink="purple">

<div style="font-family:Times New Roman;">

<p align="right" style="color:windowtext;line-height:normal;margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.1</font></b></p>

<p align="left" style="color:windowtext;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="49%" valign="top" style="padding:0in .7pt 0in .7pt;width:49.84%;">
  <p align="left" style="color:windowtext;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><b><font size="3" face="Times New Roman" style="font-weight:bold;letter-spacing:-.15pt;"><img width="158" height="59" src="g150631mmimage002.jpg"></font></b></p>
  </td>
  <td width="50%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:50.16%;">
  <p align="right" style="color:windowtext;line-height:normal;margin:0in 0in .0001pt;text-align:right;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;letter-spacing:-.15pt;">NEWS RELEASE</font></b></p>
  </td>
 </tr>
</table>

<p align="left" style="color:windowtext;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="color:windowtext;line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="49%" valign="top" style="padding:0in .7pt 0in .7pt;width:49.9%;">
  <p style="color:windowtext;margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Contacts:</font></p>
  </td>
  <td width="50%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:50.1%;">
  <p align="right" style="color:windowtext;margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="49%" valign="top" style="padding:0in .7pt 0in .7pt;width:49.9%;">
  <p style="color:windowtext;margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Anika
  Therapeutics, Inc.</font></b></p>
  </td>
  <td width="50%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:50.1%;">
  <p style="color:windowtext;margin:0in 0in .0001pt 120.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PondelWilkinson
  Klein</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="49%" valign="top" style="padding:0in .7pt 0in .7pt;width:49.9%;">
  <p style="color:windowtext;margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Charles
  Sherwood, Ph.D., CEO</font></p>
  </td>
  <td width="50%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:50.1%;">
  <p style="color:windowtext;margin:0in 0in .0001pt 120.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Susan Klein
  (508) 358-4315</font></p>
  </td>
 </tr>
 <tr>
  <td width="49%" valign="top" style="padding:0in .7pt 0in .7pt;width:49.9%;">
  <p style="color:windowtext;margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(781) 932-6616</font></p>
  </td>
  <td width="50%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:50.1%;">
  <p style="color:windowtext;margin:0in 0in .0001pt 120.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Rob Whetstone
  (310) 279-5963</font></p>
  </td>
 </tr>
</table>

<p style="color:windowtext;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="color:windowtext;font-weight:bold;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">ANIKA THERAPEUTICS SIGNS MULTI-YEAR SUPPLIER AGREEMENT</font></b></p>

<p style="color:windowtext;font-weight:bold;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">WITH BAUSCH &amp; LOMB</font></b></p>

<p style="color:windowtext;font-weight:bold;margin:0in 0in .0001pt;text-align:center;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:normal;">OrthoVisc US marketing agreement milestone payment received</font></i></b></p>

<p style="color:windowtext;font-weight:bold;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></b></p>

<p style="color:windowtext;line-height:normal;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WOBURN,
Mass. &#150; </font><font size="2" style="font-size:10.0pt;">December 20, 2004 &#150; Anika Therapeutics, Inc. (NASDAQ:ANIK) today
announced it has signed a multi-year supply agreement with the global eye
health company Bausch &amp; Lomb Incorporated (NYSE:BOL), for viscoelastic
products used in ophthalmic surgery.</font></p>

<p style="color:windowtext;line-height:normal;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="color:windowtext;line-height:normal;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Viscoelastic products, composed of hyaluronic acid,
protect delicate eye tissue and maintain eye structure during cataract and
certain refractive surgeries.</font></p>

<p style="color:windowtext;line-height:normal;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="color:windowtext;line-height:normal;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;We are pleased to announce this multi-year
agreement that extends our relationship as a major viscoelastic supplier to
Bausch &amp; Lomb, a worldwide leader in eye health products,&#148; said Charles H.
Sherwood, Ph.D., Anika&#146;s president and chief executive officer.</font></p>

<p style="color:windowtext;line-height:normal;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="color:windowtext;line-height:normal;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;We look forward to continuing our relationship with
Anika Therapeutics, which has been a supplier of viscoelastic products to
Bausch &amp; Lomb and its predecessors for more than two decades,&#148; said Thomas
J. Chambers, </font><font size="2" style="font-size:10.0pt;">Bausch
&amp; Lomb director of Global Product Strategy</font><font size="2" style="font-size:10.0pt;"> for cataract products.</font></p>

<p style="color:windowtext;line-height:normal;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="color:windowtext;line-height:normal;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In other company business, Anika separately
announced that it has received a $5 million contractual milestone payment under
a previously disclosed U.S. licensing and distribution agreement with Ortho
Biotech Products, L.P. for OrthoVisc<sup>&#174;</sup>, a treatment for osteoarthritis
of the knee.&nbsp; The payment is tied to the </font><font size="2" style="font-size:10.0pt;">incorporation of planned upgrades into Anika&#146;s
manufacturing operations. &#160;Commencing in
the fourth quarter of 2004, this cash payment will be recognized as revenue
ratably over the initial 10-year term of that agreement.</font></p>

<p style="color:windowtext;line-height:normal;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(more)</font></p>

<p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="color:windowtext;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\ykasili\04-15063-1\task257903\15063-1-mm.htm',USER='ykasilingam',CD='Dec 20 17:19 2004' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="color:windowtext;line-height:normal;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About
Anika Therapeutics, Inc.</font></b></p>

<p style="color:windowtext;line-height:normal;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="color:windowtext;line-height:normal;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Headquartered
in Woburn, Mass., Anika Therapeutics, Inc. (www.anikatherapeutics.com)
develops, manufactures and commercializes therapeutic products and devices
intended to promote the repair, protection and healing of bone, cartilage and
soft tissue.&#160; These products are based on
hyaluronic acid (HA), a naturally occurring, biocompatible polymer found
throughout the body.&#160; Anika products
include OrthoVisc<sup>&#174;</sup>, a treatment for osteoarthritis of the knee
available internationally and marketed in the U.S. by Ortho Biotech Products,
L.P., and Hyvisc<sup>&#174;</sup>, a treatment for equine osteoarthritis marketed in
the U.S. by Boehringer Ingelheim Vetmedica, Inc.&#160; It also produces CoEase<sup>&#153;</sup>, which is
marketed by Advanced Medical Optics, Inc., STAARVISC<sup>&#153;</sup>-II distributed
by STAAR Surgical Company and Shellgel<sup>&#153;</sup> for Cytosol Ophthalmics,
Inc.</font></p>

<p style="color:windowtext;line-height:normal;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="color:windowtext;margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">The
statements made in this press release which are not statements of historical
fact are forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934,
including, without limitation, statements that may be identified by words such
as &#147;expectations,&#148; &#147;remains,&#148; &#147;focus,&#148; &#147;expected,&#148; &#147;prospective,&#148; &#147;expanding,&#148; &#147;building,&#148;
&#147;continue,&#148; &#147;progress,&#148; &#147;efforts,&#148; &#147;hope,&#148; &#147;believe,&#148; &#147;objectives,&#148; &#147;opportunities,&#148;
&#147;will,&#148; &#147;seek&#148; and other expressions which are predictions of or indicate
future events and trends and which do not constitute historical matters. These
statements also include statements regarding: (i) the Company&#146;s efforts and
expectations in entering into long-term arrangements to market and distribute
ophthalmic products, (ii) the level of the Company&#146;s revenue or sales in particular
geographic areas and/or for particular products, (iii) the market share of any
of the Company&#146;s products, (iv) the Company&#146;s intention to strengthen, expand
and grow its ophthalmic franchise and the growth of the Company&#146;s ophthalmic
business, and (v) the Company&#146;s corporate objectives and research and
development and collaboration opportunities. These statements are based upon
the current beliefs and expectations of the Company&#146;s management and are
subject to significant risks, uncertainties and other factors. The Company&#146;s
actual results could differ materially from any anticipated future results,
performance or achievements described in the forward-looking statements as a
result of a number of factors including: (i) the Company&#146;s ability to successfully
commence and/or complete clinical trials of its products on a timely basis or
at all, obtain clinical data to support a pre-market approval application
and/or FDA approval, and/or receive FDA or other regulatory approvals of its
products, or that such approvals will not be obtained in a timely manner or
without the need for additional clinical trials; (ii) the Company&#146;s research
and product development efforts and their relative success, including whether
the Company has any meaningful sales of any new products resulting from such
efforts; or (iii) future determinations by the Company to allocate resources to
products and in directions not presently contemplated. Any delay in receiving
any regulatory approvals may adversely affect the Company&#146;s competitive
position. Even if regulatory approvals are obtained, there is a risk that
meaningful sales of the products may not be achieved. There is also a risk that
(i) the Company&#146;s existing distributors or customers will not continue to place
orders at historical levels or that any of them will seek to modify or
terminate existing arrangements, (ii) the Company&#146;s efforts to enter into
long-term marketing and distribution arrangements will not be successful, (iii)
new supply arrangements, including the agreement with Bausch &amp; Lomb
pertaining to viscoelastic products, will not result in meaningful sales of the
Company&#146;s products, (v) competitive products will adversely impact the Company&#146;s
product sales, (vi) the estimated size(s) of the markets to which the Company
has targeted its products will fail to be achieved, or (vii) increased sales of
the Company&#146;s products, including its ophthalmic products, will not continue or
sales will decrease or not reach historical sales </font></i></p>

<p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>

<div style="color:windowtext;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\ykasili\04-15063-1\task257903\15063-1-mm.htm',USER='ykasilingam',CD='Dec 20 17:19 2004' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="color:windowtext;margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">levels,
or even if such increases occur that such increases will improve gross margins,
any of which may have a material adverse effect on the Company&#146;s business and
operations. Certain other factors that might cause the Company&#146;s actual results
to differ materially from those in the forward-looking statements include those
set forth under the headings &#147;Business,&#148; &#147;Risk Factors and Certain Factors
Affecting Future Operating Results&#148; and &#147;Management&#146;s Discussion and Analysis
of Financial Condition and Results of Operations&#148; in each of the Company&#146;s
Annual Reports on Form 10-K for the year ended December 31, 2003, and its
Quarterly Report on Form 10-Q for the quarter ended September 30, 2004, and
Current Reports on Form 8-K, as well as those described in the Company&#146;s other
press releases and SEC filings.</font></i></p>

<p style="color:windowtext;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">###</font></p>

<p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>

<div style="color:windowtext;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\ykasili\04-15063-1\task257903\15063-1-mm.htm',USER='ykasilingam',CD='Dec 20 17:19 2004' -->


</body>

</html>

